Adriamycin in the treatment of childhood acute leukemia. A Southwest Oncology Group study.

Journal Article (Journal Article)

Sixty-six children with acute leukemia, in advanced stages of their disease and resistant to conventional chemotherapy, received adriamycin for remssion induction. Seventeen of 46 (37%) evaluable children with acute lymphocytic leukemia achieved a complete remission, and 5 (11%) achieved a partial remission. Two of 12 evaluable children with acute myelogenous leukemia achieved a complete remission, while an additional 3 achieved a partial remission. Two children with erythroleukemia also achieved a complete remission. Previous therapy with daunorubicin did not affect the response rate. The main toxicities observed with adriamycin were myelosuppression, fever, nausea and vomiting, stomatitis, alopecia, and cardiac toxicity (ST segment changes and arrhythmias).

Full Text

Duke Authors

Cited Authors

  • Ragab, AH; Sutow, WW; Komp, DM; Starling, KA; Lyon, GM; George, S

Published Date

  • October 1, 1975

Published In

Volume / Issue

  • 36 / 4

Start / End Page

  • 1223 - 1226

PubMed ID

  • 1058045

International Standard Serial Number (ISSN)

  • 0008-543X

Digital Object Identifier (DOI)

  • 10.1002/1097-0142(197510)36:4<1223::aid-cncr2820360407>;2-7


  • eng

Conference Location

  • United States